» Articles » PMID: 35911692

Distinct Type I Interferon Subtypes Differentially Stimulate T Cell Responses in HIV-1-Infected Individuals

Overview
Journal Front Immunol
Date 2022 Aug 1
PMID 35911692
Authors
Affiliations
Soon will be listed here.
Abstract

The expression of type I interferons (IFNs) is one of the immediate host responses during most viral infections. The type I IFN family consists of numerous highly conserved IFNα subtypes, IFNβ, and some others. Although these IFNα subtypes were initially believed to act interchangeably, their discrete biological properties are nowadays widely accepted. Subtype-specific antiviral, immunomodulatory, and anti-proliferative activities were reported explained by differences in receptor affinity, downstream signaling events, and individual IFN-stimulated gene expression patterns. Type I IFNs and increased IFN signatures potentially linked to hyperimmune activation of T cells are critically discussed for chronic HIV (human immunodeficiency virus) infection. Here, we aimed to analyze the broad immunological effects of specific type I IFN subtypes (IFNα2, IFNα14, and IFNβ) on T and NK cell subsets during HIV-1 infection and . Stimulation with IFNα14 and IFNβ significantly increased frequencies of degranulating (CD107a) gut-derived CD4 T cells and blood-derived T and NK cells. However, frequencies of IFNγ-expressing T cells were strongly reduced after stimulation with IFNα14 and IFNβ. Phosphorylation of downstream molecules was not only IFN subtype-specific; also, significant differences in STAT5 phosphorylation were observed in both healthy peripheral blood mononuclear cells (PBMCs) and PBMCs of HIV-infected individuals, but this effect was less pronounced in healthy gut-derived lamina propria mononuclear cells (LPMCs), assuming cell and tissue specific discrepancies. In conclusion, we observed distinct type I IFN subtype-specific potencies in stimulating T and NK cell responses during HIV-1-infection.

Citing Articles

IFNα Subtypes in HIV Infection and Immunity.

Karakoese Z, Ingola M, Sitek B, Dittmer U, Sutter K Viruses. 2024; 16(3).

PMID: 38543729 PMC: 10975235. DOI: 10.3390/v16030364.


Sex-dependent differences in type I IFN-induced natural killer cell activation.

Pujantell M, Skenteris N, Claussen J, Grunhagel B, Thiele R, Altfeld M Front Immunol. 2024; 14:1277967.

PMID: 38162640 PMC: 10757368. DOI: 10.3389/fimmu.2023.1277967.


Immunotherapy-induced cytotoxic T follicular helper cells reduce numbers of retrovirus-infected reservoir cells in B cell follicles.

Malyshkina A, Bayer W, Podschwadt P, Otto L, Karakoese Z, Sutter K PLoS Pathog. 2023; 19(10):e1011725.

PMID: 37883584 PMC: 10602292. DOI: 10.1371/journal.ppat.1011725.


Type I interferon subtypes differentially activate the anti-leukaemic function of natural killer cells.

Barnes S, Audsley K, Newnes H, Fernandez S, de Jong E, Waithman J Front Immunol. 2022; 13:1050718.

PMID: 36505400 PMC: 9731670. DOI: 10.3389/fimmu.2022.1050718.


IFNα subtype-specific susceptibility of HBV in the course of chronic infection.

Xie X, Karakoese Z, Ablikim D, Ickler J, Schuhenn J, Zeng X Front Immunol. 2022; 13:1017753.

PMID: 36311794 PMC: 9616162. DOI: 10.3389/fimmu.2022.1017753.

References
1.
Crotti A, Chiara G, Ghezzi S, Lupo R, Jeeninga R, Liboi E . Heterogeneity of signal transducer and activator of transcription binding sites in the long-terminal repeats of distinct HIV-1 subtypes. Open Virol J. 2009; 1:26-32. PMC: 2675545. DOI: 10.2174/1874357900701010026. View

2.
Harper M, Guo K, Gibbert K, Lee E, Dillon S, Barrett B . Interferon-α Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms. PLoS Pathog. 2015; 11(11):e1005254. PMC: 4631339. DOI: 10.1371/journal.ppat.1005254. View

3.
McNab F, Mayer-Barber K, Sher A, Wack A, OGarra A . Type I interferons in infectious disease. Nat Rev Immunol. 2015; 15(2):87-103. PMC: 7162685. DOI: 10.1038/nri3787. View

4.
Platanias L . Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005; 5(5):375-86. DOI: 10.1038/nri1604. View

5.
Herbeuval J, Nilsson J, Boasso A, Hardy A, Kruhlak M, Anderson S . Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci U S A. 2006; 103(18):7000-5. PMC: 1444883. DOI: 10.1073/pnas.0600363103. View